Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Available exclusively in the U.S
Phase 3 TRIUMPH Programme Retatrutide has now entered the Phase 3 TRIUMPH clinical programme, one of the most expansive trial programmes currently underway in obesity and metabolic medicine
The Triple Threat A new player on the horizon is retatrutide, known as a GIP/GLP-1/glucagon receptor triple agonist
Observed responses may vary depending on research amount, administration frequency, protocol duration, physiological status, inflammatory status, and individual sensitivity
Way SW, McKenna IIIJ, Mietzsch U, Reith RM, Wu HC-J, Gambello MJ
US$ 29.75
US$ 24.77
US$ 20.34
US$ 24.69
US$ 26.74
US$ 21.22
US$ 21.67
US$ 23.88
US$ 27.11
US$ 25.45
US$ 28.57
